[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

Re: [IP] Re: Finding a cure?

Hi Steve,

You've done you homework!!!!
I hope everyone in our group reads
what you've found. I'd like to hear
other group member's comments
about you said.

Keep making people think,


email @ redacted wrote:
> An article from Diabetes in Control that lends a viewpoint to our discussion:
>  bThe Perfect Diseaseb
> Diabetes has no cure, and it consumes 1 out of every 7 health care dollars
> and adds up to over 100 Billion dollars a year.
> Diabetes is big business with 25% of our Medicare budget going towards
> treating it and with an increase of over 70% in the 30 year olds and 30%
> increase in teenagers with diabetes over the last couple of years and it is
> going to get even bigger.  The American Diabetes Association (ADA) says Type
> 2 diabetes is nearing (it actually is) epidemic proportions because Americans
> are aging, getting fatter and are more sedentary.  At greatest risk; lazy,
> fat people over 30, with a family history of diabetes.  Diabetes is one of
> the most costly health problems in the US and in the world b with a tab of
> over 100 billion dollars and growing in the US alone.
> Diabetes drugs, the fastest growing category, cost $3.5 billion a year.  But
> then there are diagnostic systems, delivery systems, needlesb&b&b&
> There is no cure and it is a progressive disease, and as the UKPDS has shown
> us, no matter what you do, it will always get worse over time.   So when a
> doctor prescribes a drug, we know it will fail eventually.   As long as we
> treat the complications from diabetes, it will continue to be a drain on our
> healthcare industry, but a boom to our economy.
> It is a perfect disease from a business perspective because patients need a
> large and steady supply of drugs, diagnostic and delivery devices and lots of
> disposables like lancets, syringes and test strips, among other things.
> Diabetics are very receptive to any technology that makes life simpler and
> cheaper.
> It is a perfect disease from a medical professionals perspective because once
> you have a diabetic patient and you build a relationship, you can have that
> patient for life who makes an office visit at least 2-12 times a year.
> It is a perfect disease for the patient because the patient controls 95% of
> the outcome.   It also causes the patient to become educated about their
> disease in order to control it and if they do everything right,  they will be
> in better health then 90% of the people in their age group.
> There is a race not to cure or prevent the disease but to market products to
> treat it. Diabetes has attracted an array of players, from large drug makers
> to companies working on new drugs with milder side effects, to companies
> wanting to deliver insulin via painless needles, orally or into the lung, to
> device makers with better insulin delivery pumps, to companies making
> diagnostic and continuous monitoring tools.
> The field is crowded but the investment potential is massive and itbs tied
> to
> solid growth trends, this is big business.  At 6% and growing and 16 million
> Americans and 100 million diabetics worldwide and 2,200 new diabetics are
> diagnosed every day in the U.S. so,  800,000 will be diagnosed this year in
> the US alone says the ADA.  That means an additional 5 billion dollars spent
> every year in just medications and supplies.
> The ADA reports 10.3 million diabetics have been diagnosed, but an additional
> 5.4 million people have it and donbt know.  One day they will.  Then they
> will be faced with spending $2,500 to $3,500 dollars a year on needles,
> drugs, insulin and blood testing strips.  For 50% of those that get
> diagnosed, they would have had diabetes for up to 12 years before and will
> already have signs of the complications, which will mean even more expenses.
> The total annual economic cost of diabetes in the US alone in 1997 was 98
> billion dollars.  That included $44 billion in medical costs.   The other $54
> billion is the indirect costs of disability and mortality.
> The top pharmaceutical companies dominate the field with billion-dollar
> diabetes drugs.
> Bristol-Myers Squibb makes the insulin sensitizer drug Glucophage.  Itbs
> used
> mainly by the older population for Type 2 diabetes and had sales of $1.3
> billion in 1999.  They are also co-developing Basulin, a form of long-acting
> insulin.
> Eli Lilly makes insulin and the Type 2 insulin sensitizer drug Actos, which
> was launched in August 1999 and racked up sales of $147 million in its first
> five months.
> SmithKline Beecham introduced the insulin sensitizer drug Avandia in June
> 2000
> Novo Nordisk makes and sells insulin as well as the insulin secretion drug
> Prandin and is soon expected to launch NovoLog, a fast-acting insulin.
> Pfizer makes the sulfonylureas Glucotrol and Glucotrol XL.  Sulfonylureas are
> a $500 million- a b year class of drugs that help the body produce more
> insulin.  Pfizer now owns Warner Lambert, the maker of the antidiabetic drug
> Rezulin, which was the first insulin sensitizer, which was launched in 1997
> and posted annual sales of $625 million.  In March 2000, the drug was
> withdrawn for causing liver damage.
> Aventis also makes two sulfonylureas, Amaryl and Diabeta, as well as insulin.
>  It is soon to launch a new insulin product Lantus, a biosynthetic insulin
> that mimics human insulin and will last for 24 hours.
> Novartis is planning a 2001 launch for Starlix, a new drug for Type 2
> diabetes which is similar to Prandin and just received FDA approval last
> week.
> At least 3 companies are working to deliver insulin without needles.  Aradigm
> is collaborating with Novo Nordisk to develop inhaled insulin.  Inhale
> Therapeutics considered the leader in deep-lung drug delivery, is developing
> inhaled insulin with Pfizer.  Eli Lilly has an agreement with Dura
> Pharmaceuticals to develop inhaled insulin.
> Canadian-based Generex Biotechnology is developing orally delivered insulin
> that appears to deliver at levels on par with injections.  The insulin will
> be delivered through the lining of the check  they believe it is possible to
> get an accurate dose via a mouth spray.  The drug takes effect within 10
> minutes of use.  The company says it found no adverse reactions in tests and
> is now doing trials on Type 1 and 2 diabetes in the US and Canada.  They just
> completed a $23 million private placement and will use the money to expand
> the trials.  In September it entered into an agreement with Eli Lilly for the
> oral formulation.
> Abbott Labs is the largest of the diagnostic and medical device companies
> working on diabetes.  Abbott makes precision glucose meters and is
> co-developing a continuous glucose monitor with SpectRX.  The monitor will
> regularly check the personbs blood to see how much, if any,  insulin is
> needed.  Inverness Medical Technology also makes devices and disposable
> products for diabetes.
> Becton Dickinson makes insulin delivery products b needles, lancets and
> syringes b all items used daily by millions of diabetics.  It is the biggest
> producer by far.  Its products could be duplicated and sold more cheaply
> through private labels but it has effectively kept competitors out of major
> distributions with restrictive market agreements.  But some of the chains
> like Walgreens and Walmart have committed to private labeling.
> Amylin Pharmaceuticals, Alteon, OSI Pharmaceuticals and Insmed are working on
> new classes of drugs for diabetes.  Mini-Med and Cygnus are working on
> glucose monitors.
> MiniMed controls 85% of the market for pumps but Disetronic a swiss firm and
> Animas a US firm are making inroads and will heat up the competition for the
> insulin pump market which is growing at the rate of 80% a year.  Pumps right
> now are the only available treatment that provides insulin continuously b
> the
> preferred way.  The cost of using a pump is per year is about $700 compared
> to the $1200-$2400 for injections and other conventional approaches.  The
> Pumps sell for over $5000, but lasts for years MiniMed also markets a
> continuous glucose monitor, but there are at least 5 other companies doing
> research on their own continuous glucose monitor.  One of those is a company
> that is developing a continuous glucose monitor that is implanted and works
> for over a year and sends readings to a computer.  All of these companies are
> working on a continuous loop insulin pump, where a monitoring device measure
> the amount of glucose in the blood and sends the information to the pump to
> give you the exact amount of insulin your body requires, just like your own
> pancreas, but you will be wearing it.
> Inverness Medical Technology makes blood glucose monitors, glucose test
> strips under its own brands and for private label retailers as Rite Aid,
> Walgreens and Wal-Mart
> Johnson & Johnson make the Lifescan products and holds the competitive edge
> in blood glucose monitors and strips.  Bayer labs, Abbott Labs, Roche
> diagnostics, and LXN Corp are all trying to eat in to their market share,
> spending millions in advertising and R & D.
> Cygnusb GlucoWatch is all the rage in continuous glucose monitoring.  The
> wrist-worn device monitors blood-sugar levels and gives readings every five
> minutes.  Its electro-osmosis system checks the patientbs blood-sugar levels
> without breaking the skin, a huge benefit.   The FDA is deliberating on the
> product now, but customers will be disappointed with how the product works.
> Among the drawbacks, is a 3-hour warm-up period.  The watch must also be
> calibrated before use with the patientbs blood, this means finger sticks
> using lancets.  High and low readings have to be confirmed with tests on
> other devices, so more finger sticks.
> One of the newest concepts in continuous glucose monitoring systems is being
> developed by SpectRx who has an agreement with Abbott to market the system
> when it gets approved.   Its products use biophotonic technology based on
> light beams to make medical diagnosis.  The plan is to have a single-use and
> continuous glucose-monitoring device that uses lasers and vacuums to
> penetrate and remove fluid through the skin.
> Amylin Pharmeceuticals is developing diabetes drugs based on the hormone
> amylin, which is believed to play a role in metabolic controls.  The company
> develops Symlin for Type 1 and insulin-using Type 2 diabetics.  It completed
> phase III trials for Symlin and plans to apply for FDA approval by the end of
> 2000.  But in October, Amylin successfully completed the feasibility stage of
> its collaboration with Alkermes for the development of an injectable
> long-acting release formulation of its drug AC2993, for Type 2 diabetes.  The
> goal is a formulation that would allow once-a-month administration.
> Insmedbs main candidate INS-1, an oral formulation, fights Type 2 diabetes
> and polycyctic ovary syndrome, which cause infertility in women.
> Genomics companies are also targeting diabetes.  Lynx Therapeutics and
> Genomics Collaborative will be doing a comprehensive genome-wide scan for
> single nucleotide polymorphisms, or SNPs, that are associated with Type 2
> diabetes.  These SNP markers could lead to the discovery of diabetic gene
> targets and pathways, as well as diagnostic markers for the onset and
> progression of Type 2 diabetes.  This will allow us to due preventative
> medicine and help to prevent those that will become diabetic.
> These are most of the major players in the diabetes field, but there are many
> more small companies that are working to develop products for people with
> diabetes.
> Is this the perfect disease?
> Steve Freed, R.Ph., CDE
> Publisher
> ----------------------------------------------------------
> for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
> send a DONATION http://www.Insulin-Pumpers.org/donate.shtml
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml